– USA, NC – NephroGenex, Inc. (NASDAQ:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced the appointment of Marco Taglietti, M.D., to its Board of Directors. Dr. Taglietti has more than 20 years of experience in senior leadership positions in pharmaceutical research and development, most recently at Forest Laboratories, Inc.
“We are extremely pleased to have Dr. Taglietti join our board, and look forward to the critical perspective he can bring to the clinical development of Pyridorin, our Phase 3 compound to treat diabetic kidney disease.”
“Dr. Taglietti has an impressive track record of leading global R&D operations, and has overseen the development and worldwide approvals of dozens of important therapeutic products,” said NephroGenex Chief Executive Officer Pierre Legault. “We are extremely pleased to have Dr. Taglietti join our board, and look forward to the critical perspective he can bring to the clinical development of Pyridorin, our Phase 3 compound to treat diabetic kidney disease.”
Prior to its recent acquisition, Dr. Taglietti served as Executive Vice President, Research and Development, and Chief Medical Officer of Forest Laboratories, Inc. He also served as President, Chief Medical Officer of the Forest Research Institute. Prior to joining Forest Labs in 2007, Dr. Taglietti held the position of Senior Vice President, Head of Global Research and Development, at Stiefel Laboratories, Inc. for three years. He joined Stiefel after 12 years at Schering-Plough Corporation where he last held the position of Vice President, Worldwide Clinical Research for Anti-Infectives, Oncology, CNS, Endocrinology and Dermatology. Dr. Taglietti began his career at Marion Merrell Dow Research Institute. Over the course of his career, he has brought to market 35 different products in the U.S. and internationally. He received his medical degree and board certifications from the University of Pavia in Italy.
Dr. Taglietti joins Nephrogenex’s Board of Directors as an independent director, serving on the Audit and Compensation Committees.
About NephroGenex, Inc.
NephroGenex (NASDAQ:NRX) is a clinical-stage pharmaceutical company focused on developing therapeutics to treat kidney diseases caused by pathogenic oxidative chemistries. Since our inception, we have collaborated with the leading scientific experts in pathogenic oxidative chemistries to build a strong portfolio of intellectual property and novel acting drug candidates. Our clinical program has been done in collaboration with world leading clinical investigators in kidney disease. Our product pipeline includes an oral formulation of PYRIDORIN® (pyridoxamine dihydrochloride), which is being developed as a chronic, therapeutic agent to slow the progression of diabetic nephropathy, as well as an intravenous formulation of Pyridorin to treat specific types of acute kidney injury.
- Disclaimer - News, data and statement included in this release are intended exclusively for information purposes. Product and brand names used in this release maybe trademarks or registered trade marks of their respective owners. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of this release. No data or statement in this release should be considered a recommendation for the purchase, retention or sale of the securities referred to herein.
Comments are closed.